With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026

BioSpace

With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.

CommercialRead full story